FJFreyja Jónsdóttir

Freyja Jónsdóttir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Freyja Jónsdóttir has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological Prevention and Treatment of Delirium: A Systematic Review of Published Clinical Psychiatry Guidelines

    by Ivana Tadić, Freyja Jónsdóttir, Marianna Koroly, Renate Groß, Anita Elaine Weidmann

    Purpose of Review: Delirium due to an underlying causal condition or etiology is a common complication in hospitalized patients, especially among older individuals. Due to its complex nature and similarity in appearance with other psychiatric and neurological conditions, delirium is often unrecognised or wrongly diagnosed. Clinical guidelines should guide treatment decisions but there is a lack of clear, comprehensive, and easily implementable guidelines. The purpose of this review is to summarize the information provided by psychiatry guidelines on pharmacological causes, treatment options, and alternatives in adult delirium patients (> 18 years) with and without dementia, thereby facilitating patient management and care in psychiatric settings. Recent Findings: The systematic review analyzed information from six international clinical guidelines aimed at treating patients with delirium. All guidelines focused on delirium with only one guideline offering some additional information on the treatment of delirium in dementia patients. Among all the medications listed in relation to, antipsychotics are the most frequently recommended. Only one guideline provides more detailed information on dosages, therapy duration and pharmacokinetic profiles in relation to individual medicines. Clinical guidelines are based on original studies that contain significant inconsistencies in medication efficacy, leading to a paucity of specific information in these guidelines and considerable discrepancies among them. Summary: There is still a need for clear and consistent evidence on pharmacological causes, treatment options, and alternatives in adult delirium patients (>18 years) with and without dementia.

  • Open Access

    Exploring the association between medication, patient-specific factors and delirium in hospitalised patients: a 10-year retrospective, population-based cohort study in Iceland

    by Anita E Weidmann, Julia A Schintler, Reto Stauffer, Martin I Sigurðsson, Freyja Jónsdóttir

    Objectives: This study aimed to identify potential significant statistical associations between the development of delirium, medication and several other patient-specific factors across a 10-year retrospective longitudinal real-world dataset. Design: A retrospective, population-based cohort study. Setting: The National University Hospital of Iceland. Participants: All patients≥18 years hospitalised between 2010 and 2020. Primary and secondary outcome measures: The primary outcome was a diagnosis of delirium within 2 years of a patient filling a prescription for a specific medication. The exposure was pre-admission medication use or a pre-existing condition. Secondary outcomes included mortality, length of hospital stay, readmission rate and frequency of additional delirium diagnosis. Results: A total of 85 942 admissions and readmissions were included in the dataset, which comprised 1066 variables. The cohort comprised 55 495 patients (51.5% male) with a median [IQR] age of 71 years [58, 82]. Throughout the study, 3533 patients were diagnosed with delirium at least once over the 10-year study period. A statistically significant association (χ 2 test, p <0.001) between the delirium (n=3533) and the non-delirium group (n=51 926) was identified for hyperpolypharmacy (≥10 medications), prescribed proton pump inhibitors, opioids, beta-lactam antibiotics, anticoagulants, statins and selective beta-blockers. Delirium was associated with an extended hospital stay, an increased readmission rate and increased mortality. No significant statistical association was found between delirium and the use of tricyclic antidepressants (p=0.121), nor with the presence of type I diabetes (p=0.216). On an annual average, the prevalence of patients who had obtained a delirium diagnosis within the previous year and were subsequently diagnosed again with delirium during their admission was 25.7%. Conclusion: Numerous medications and other patient-specific risk factors have been identified, which underlines the complexity of delirium development. To strengthen patient safety and hinder the development of delirium, an increased emphasis is needed to review medication use and improve our understanding of medication risk associated with delirium cause, treatment and prevention. Specific prescribing/deprescribing advice should be developed to inform prescribing practice and patient safety.

  • Inappropriate Medication Use and Association With Polypharmacy in Surgical Patients: A Retrospective, Population‐Based Cohort Study

    by Freyja Jónsdóttir, Anna B. Blöndal, Aðalsteinn Guðmundsson, Ian Bates, Jennifer M. Stevenson, Martin I. Sigurðsson

    Background: This study assessed the prevalence and incidence of potentially inappropriate medication use for older patients undergoing surgery and its association with polypharmacy.Methods: A retrospective, population‐based cohort study with patients ≥ 65 undergoing first surgery at Landspitali—The National University Hospital of Iceland from 2005 to 2018. Participants were categorized by number of medications filled before and following their surgical episode into: non‐polypharmacy (< 5), polypharmacy (5–9), and hyper‐polypharmacy (≥ 10). The prevalence and incidence of PIM use were compared between polypharmacy categories based on the 2019 Beers criteria.Results: A total of 17,198 admissions associated with surgery were assessed (53.8% female) with a median [IQR] age of 75 [70, 81]. The prevalence of potentially inappropriate medication among patients with non‐polypharmacy (< 5) was 36.6% (95% CI: 35.1–38.2), with polypharmacy (5–9) 80.2% (95% CI: 79.2–81.2), and with hyper‐polypharmacy 95.8% (95% CI: 95.3–96.2). New potentially inappropriate medication use post‐surgery occurred in 38.5% (95% CI: 37.0–40.1). Risk factors included female sex, increased comorbidity, and prior use of a multidose dispensing service. Compared with patients without potentially inappropriate medication use, patients with potentially inappropriate medication use had a higher rate of postoperative diagnosis of medication‐related harm (12.6% vs. 11.3%), increased 30‐day mortality (5.2% vs. 0.3%), longer hospital stay (3 [1, 8] vs. 2 [1, 5] days), and increased 30‐day readmission rate (11.3% vs. 6.5%).Conclusions: Potentially inappropriate medication use is strongly associated with polypharmacy/hyper‐polypharmacy and adverse outcomes in older surgical patients. Surgical hospitalization offers a critical window for medication review, deprescribing, and follow‐up planning to reduce medication‐related harm.


  • Open Access

    Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability

    by Ivar Veszelei, Brian Godman, Katri Aaltonen, Gisbert W. Selke, Kristina Garuolienė, Agnese Cangini, Amanj Kurdi, António Teixeira Rodrigues, Caridad Pontes, Carla Torre, et al.

    Biopharmaceuticals add value in the treatment of many diseases but different health systems in Europe face clinical and economic challenges with introducing them. Joint efforts across Europe are therefore essential to ensure their sustainable and equitable use. However, to date few cross-national comparative studies have assessed their introduction. This study aimed to assess the availability of health authority data and variation in the early diffusion of biopharmaceuticals across Europe. A cross-sectional study was undertaken to analyze the diffusion of 17 biopharmaceuticals, approved between 2015 and 2019, among European countries between 2015 and 2022. The study assessed data availability, diffusion rates measured as accumulated defined daily doses per 1000 inhabitants, as well as relative rankings between countries during the first 4 years following market authorization. Twenty countries and two regions out of 31 European countries provided data on biopharmaceutical utilization for out-of-hospital care, 15 provided wholesaler data, and 14 provided hospital data. Certain countries and regions contributed data in multiple categories, while six did not provide any data. Diffusion rates were assessed for 17 countries and two regions, which showed appreciable variation, with secukinumab and erenumab being introduced in most countries and follitropin delta and tildrakizumab in the least number of countries. Germany, Austria, and Norway demonstrated the highest early diffusion rates, while Lithuania, Romania, and Latvia had the lowest. This study revealed a substantial variation between European countries and regions in the early diffusion of biopharmaceuticals and the availability of data to monitor their use. The reasons behind these patterns require further investigation to support European countries in optimizing the use of biopharmaceuticals to reach an equitable and cost-effective use of medicines across Europe.


  • Open Access

    Medication-induced causes of delirium in patients with and without dementia: a systematic review of published neurology guidelines

    by Anita Elaine Weidmann, Guðný Björk Proppé, Rut Matthíasdóttir, Ivana Tadić, Pétur Sigurdur Gunnarsson, Freyja Jónsdóttir

    Background: While medication is a recognized risk factor of delirium, there is currently a lack of detailed information on managing and preventing medication-induced cases. Aim: This review summarizes the information provided in neurology guidelines on medication-induced delirium in patients with and without dementia to inform guidance on prevention and management strategies. Method: A systematic literature review was conducted across 114 neurological and medical organisations, Guideline Central and PubMed. Guidelines, consensus guidelines, white papers, frameworks, protocols, standard procedures, action plans and strategic documents detailing the prevention and management of medication-induced delirium in adults with or without dementia were included. Title and full-text screening was completed independently by two reviewers using PICOS. AGREE II was used to assess reporting quality. A data extraction tool was designed based on the Cochrane Effective Practice and Organization of Care Review Group (EPOC) checklist and a mixed methods approach to synthesis adopted. The systematic review protocol was registered with International Prospective Register of Systematic Reviews (PROSPERO) [ID: CRD42022366025]. Results: Out of 143 guidelines identified, 30 were included. Information for 140 individual medications was extracted. Medications most frequently cited included sedatives (n = 24/80%), opioids (n = 22/73,3%), psychoactive drugs (n = 21/70%) + anti-convulsants (n = 14/46,7%), anti-cholinergic agents (n = 20/66,7%), antihistamines (n = 18/60%), and steroids (n = 16/53,3%). Despite a consistently high-quality rating (n = 19, 63,3%), the detail provided often lacks specificity about pharmacological mechanisms, individual risk, dosing instructions, associated symptoms, therapeutic alternatives and avoidable drug-drug combinations. In relation to dementia, detailed information on the use of antipsychotics, cholinesterase inhibitors and benzodiazepines was extracted. No papers were excluded based on their quality. Conclusion: No single guideline contains enough information on the risk, prevention, and management of medication-induced delirium to sufficiently support clinical decision making.


  • Potentially Inappropriate Medication Use and Polypharmacy Before and After Admission to Internal Medicine for Older Patients

    by Freyja Jónsdóttir, Anna B. Blöndal, Aðalsteinn Guðmundsson, Ian Bates, Jennifer M. Stevenson, Martin I. Sigurðsson


  • Open Access

    The association of degree of polypharmacy before and after among hospitalised internal medicine patients and clinical outcomes: a retrospective, population-based cohort study

    by Freyja Jonsdottir, Anna B Blondal, Adalsteinn Gudmundsson, Ian Bates, Jennifer Mary Stevenson, Martin I Sigurdsson

    Objectives To determine the prevalence and incidence of polypharmacy/hyperpolypharmacy and which medications are most prescribed to patients with varying burden of polypharmacy. Design Retrospective, population-based cohort study. Setting Iceland. Participants Including patients (≥18 years) admitted to internal medicine services at Landspitali – The National University Hospital of Iceland, between 1 January 2010 with a follow-up of clinical outcomes through 17 March 2022. Main outcomes measures Participants were categorised into medication use categories of non-polypharmacy (10) based on the number of medications filled in the year predischarge and postdischarge. The primary outcome was prevalence and incidence of new polypharmacy. Secondary outcomes were mortality, length of hospital stay and re-admission. Results Among 85 942 admissions (51% male), the median (IQR) age was 73 (60–83) years. The prevalence of preadmission non-polypharmacy was 15.1% (95% CI 14.9 to 15.3), polypharmacy was 22.9% (95% CI 22.6 to 23.2) and hyperpolypharmacy was 62.5% (95% CI 62.2 to 62.9). The incidence of new postdischarge polypharmacy was 33.4% (95% CI 32.9 to 33.9), and for hyperpolypharmacy was 28.9% (95% CI 28.3 to 29.5) for patients with preadmission polypharmacy. Patients with a higher level of medication use were more likely to use multidose drug dispensing and have a diagnosis of adverse drug reaction. Other comorbidities, including responsible subspeciality and estimates of comorbidity and frailty burden, were identical between groups of varying polypharmacy. There was no difference in length of stay, re-admission rate and mortality. Conclusions Preadmission polypharmacy/hyperpolypharmacy and postdischarge new polypharmacy/hyperpolypharmacy is common amongst patients admitted to internal medicine. A higher level of medication use category was not found to be associated with demographic, comorbidity and clinical outcomes. Medications that are frequently inappropriately prescribed were among the most prescribed medications in the group. An increased focus on optimising medication usage is needed after hospital admission. Trial registration number NCT05756400.


  • The epidemiology of new persistent hypnotic/sedative use after surgical procedures: a retrospective cohort study

    by D. H. Magnusson, T. I. Albertsson, F. Jonsdottir, M. I. Sigurdsson

    Summary: The use of hypnotic and sedative medication for sleep improvement is common and long‐term use has been associated with an increased risk of adverse events and mortality. A proportion of patients might develop long‐term use after initiating new persistent use following surgery. This retrospective cohort study aimed to determine the incidence of new persistent hypnotic/sedative use after surgical procedures and associated patient and procedural factors. Data on prescriptions for hypnotic and sedative medications used for sleep improvement were retrieved from the National Prescription Medicine Registry. Medication naivety was defined as not filling a prescription for hypnotics/sedatives from 365 days through 31 days preceding surgery, new use was defined as medication naivety followed by filling a prescription for hypnotic/sedative medication from 30 days before surgery through 14 days after surgery. New persistent hypnotic/sedative use was defined as new use followed by filling another hypnotic/sedative prescription from 15 days through 365 days after surgery. Of 55,414 patients included in the study, 43,297 were naive to hypnotic/sedative medications. Of those naive patients, 4.6% met the criteria for new peri‐operative use, of whom 51.6% developed new persistent hypnotic/sedative use. Patient and procedural factors associated with increased risk of new persistent use were older age; female sex; the presence of malignant neoplasm; ischaemic heart disease; and having undergone either cardiac or thoracic surgery. The hazard of long‐term mortality was higher for patients with new persistent use (1.39, 95%CI 1.22–1.59) compared with patients who remained naive. While a small ratio of surgical patients initiates the use of hypnotics/sedatives in the peri‐operative period, a substantial proportion of these develop persistent use, which is associated with adverse outcomes. Over time, the proportion of patients using hypnotics/sedatives has declined, but the risk of persistent use within this group has remained stable.


  • Open Access

    Epidemiology and association with outcomes of polypharmacy in patients undergoing surgery: retrospective, population-based cohort study

    by Freyja Jónsdóttir, Anna B Blöndal, Aðalsteinn Guðmundsson, Ian Bates, Jennifer M Stevenson, Martin I Sigurðsson

    The aim of this study was to determine the prevalence of preoperative polypharmacy and the incidence of postoperative polypharmacy/hyper-polypharmacy in surgical patients and their association with adverse outcomes. This was a retrospective, population-based cohort study among patients older than or equal to 18 years undergoing surgery at a university hospital between 2005 and 2018. Patients were categorized based on the number of medications: non-polypharmacy (fewer than 5); polypharmacy (5–9); and hyper-polypharmacy (greater than or equal to 10). The 30-day mortality, prolonged hospitalization (greater than or equal to 10 days), and incidence of readmission were compared between medication-use categories. Among 55 997 patients, the prevalence of preoperative polypharmacy was 32.3 per cent (95 per cent c.i. 33.5 to 34.3) and the prevalence of hyper-polypharmacy was 25.5 per cent (95 per cent c.i. 25.2 to 25.9). Thirty-day mortality was higher for patients exposed to preoperative hyper-polypharmacy (2.3 per cent) and preoperative polypharmacy (0.8 per cent) compared with those exposed to non-polypharmacy (0.6 per cent) (P < 0.001). The hazards ratio (HR) of long-term mortality was higher for patients exposed to hyper-polypharmacy (HR 1.32 (95 per cent c.i. 1.25 to 1.40)) and polypharmacy (HR 1.07 (95 per cent c.i. 1.01 to 1.14)) after adjustment for patient and procedural variables. The incidence of longer hospitalization (greater than or equal to 10 days) was higher for hyper-polypharmacy (11.3 per cent) and polypharmacy (6.3 per cent) compared with non-polypharmacy (4.1 per cent) (P < 0.001). The 30-day incidence of readmission was higher for patients exposed to hyper-polypharmacy (10.2 per cent) compared with polypharmacy (6.1 per cent) and non-polypharmacy (4.8 per cent) (P < 0.001). Among patients not exposed to polypharmacy, the incidence of new postoperative polypharmacy/hyper-polypharmacy was 33.4 per cent (95 per cent c.i. 32.8 to 34.1), and, for patients exposed to preoperative polypharmacy, the incidence of postoperative hyper-polypharmacy was 16.3 per cent (95 per cent c.i. 16.0 to 16.7). Preoperative polypharmacy and new postoperative polypharmacy/hyper-polypharmacy are common and associated with adverse outcomes. This highlights the need for increased emphasis on optimizing medication usage throughout the perioperative interval. NCT04805151 (http://clinicaltrials.gov).


  • The incidence of new and persistent benzodiazepine use after surgery

    by Þorsteinn Ívar Albertsson, Freyja Jónsdóttir, Sigurbergur Kárason, Martin I. Sigurdsson